A thyroid compound once barred as a diet supplement returns as an approved rare-disease drug
SILVER SPRING, Md., Sept. 28, 2026 — The FDA on Monday approved tiratricol, sold as Emcitate by Sweden's Egetis Therapeutics, for MCT8 deficiency, a genetic disorder estimated to affect about 1 in 70,000 males. The drug lowers the excess thyroid hormone that strains patients' hearts and leaves many underweight. It does not treat the brain effects.
The molecule has been here before. In 1999 and 2000, the FDA warned consumers against tiratricol sold through gyms and health food stores as a weight-loss supplement, calling it a potent thyroid hormone that could cause heart attacks and strokes. Regulators said one product was being promoted to treat obesity; its sellers conceded in court that it was a drug after the government disclosed an investigational drug application for it.
Tiratricol is Egetis's only product on the market. The company lost 108.9 million Swedish kronor in the second quarter on sales of 17.4 million, and raised 350 million kronor in April. It plans to sell the priority review voucher that came with the approval. Its stated next target is another rare thyroid disorder, not weight loss.
Once approved, a drug may be prescribed for other uses at a doctor's judgment, though one large insurer's draft policy requires documented eligibility. Whether weight-loss demand appears, and what it would mean for supply and price for the few patients it was approved to help, is not yet known.
The wall: No U.S. price has been announced; this desk found no reports of off-label use.
Tier: Confirmed
Sources
- FDA approval release
- FDA enforcement archive, 2001 (tiratricol/Triax)
- Egetis Q2 2026 interim report
- Egetis, RTH-beta as next indication
- FDA, off-label use of approved drugs
- Centene clinical policy CP.PHAR.790 (draft)
- Prevalence estimate (peer-reviewed review)
This newsfeed was produced and brought to you by Temporal Data Dynamics Technology. For more information, visit temporaldatadynamics.com.